1148 related articles for article (PubMed ID: 11114313)
1. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
N Engl J Med; 1994 Feb; 330(5):319-22. PubMed ID: 7904047
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine: new indication. First-line treatment of CLL: unconvincing evidence.
Prescrire Int; 2005 Feb; 14(75):3-5. PubMed ID: 15747447
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
[TBL] [Abstract][Full Text] [Related]
7. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
8. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
13. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.
Dighiero G; Maloum K; Desablens B; Cazin B; Navarro M; Leblay R; Leporrier M; Jaubert J; Lepeu G; Dreyfus B; Binet JL; Travade P
N Engl J Med; 1998 May; 338(21):1506-14. PubMed ID: 9593789
[TBL] [Abstract][Full Text] [Related]
14. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
15. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
Varga F; Lehoczky D; Demeter J
Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
[TBL] [Abstract][Full Text] [Related]
16. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F
Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
